Choroideremia (CHM) is a rare, inherited retinal disorder that leads to progressive vision loss and can ultimately result in complete blindness. It is an X-linked chorioretinal dystrophy, meaning it primarily affects males, though female carriers can sometimes experience mild symptoms. The condition is characterized by the gradual degeneration of three key layers in the eye: the choroid (the vascular layer that supplies blood to the retina), the retinal pigment epithelium (a layer of cells that nourishes the retina), and the photoreceptors (the light-sensitive cells in the retina).
The first symptom of choroideremia is typically night blindness, which often becomes noticeable in early childhood. As the disease progresses, individuals experience a gradual loss of peripheral vision, leading to "tunnel vision." This progressive narrowing of the visual field can make navigating unfamiliar environments challenging. In the later stages of the disease, usually in late adulthood, central vision is also affected, which can lead to legal or complete blindness.
The underlying cause of choroideremia is a mutation in the CHM gene, which provides instructions for producing a protein called Rab escort protein-1 (REP-1). This protein is essential for the proper functioning of cells in the retina. When the CHM gene is mutated, the REP-1 protein is either absent or non-functional, leading to the premature death of retinal cells and the subsequent loss of vision.
Diagnosing choroideremia involves a comprehensive eye examination, including tests such as electroretinography (ERG) to measure the electrical activity of the retina, optical coherence tomography (OCT) to obtain detailed images of the retinal layers, and visual field testing. Genetic testing is also crucial to confirm the diagnosis and identify the specific mutation in the CHM gene.
While there is currently no cure for choroideremia, understanding the disease is the first step in managing it. Early diagnosis allows patients and their families to plan for the future, access appropriate support services, and stay informed about emerging research and clinical trials. Patients are strongly encouraged to consult with their healthcare provider or a retinal specialist for personalized advice and management strategies.